Efficacy and Safety of Secukinumab for the Treatment of Moderate to Severe Psoriasis in Korea / 대한피부과학회지
Korean Journal of Dermatology
;
: 9-14, 2019.
Artículo
en Coreano
| WPRIM
| ID: wpr-719530
ABSTRACT
BACKGROUND:
Secukinumab, a fully human monoclonal antibody that targets interleukin (IL)-17A, which is a central cytokine in the pathogenesis of psoriasis, has emerged as a promising treatment for moderate to severe psoriasis. However, to date, there are no real-world data for secukinumab in Korean patients with psoriasis.OBJECTIVE:
To assess the clinical efficacy and safety of secukinumab in Korean patients with psoriasis.METHODS:
Prospective data were gathered during follow-up from 28 consecutive patients with chronic plaque-type psoriasis treated with secukinumab for minimum of 12 weeks at a single referral center. Patient demographics, Psoriasis Area Severity Index (PASI) score, Physicians' Global Assessment (PGA), Dermatologic Life Quality Index (DLQI), and adverse events were investigated.RESULTS:
The mean PASI score was significantly decreased after the induction period of secukinumab treatment (paired t-test, p<0.05). Of the 28 patients, 17 (60.7%) had obtained near complete clearance (PASI 90) at the last follow-up visit. No unexpected adverse events, other than nasopharyngitis, were observed.CONCLUSION:
Secukinumab can be of benefit for the treatment of Korean patients with psoriasis, as the treatment was associated with a rapid and satisfactory response and safety profile.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Psoriasis
/
Calidad de Vida
/
Derivación y Consulta
/
Demografía
/
Nasofaringitis
/
Estudios Prospectivos
/
Estudios de Seguimiento
/
Interleucinas
/
Resultado del Tratamiento
/
Corea (Geográfico)
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS